Zobrazeno 1 - 9
of 9
pro vyhledávání: ''
Autor:
Jeffrey A. Meyerhardt, Edward Giovannucci, Koichiro Haruki, Mingyang Song, Eliezer M. Van Allen, Kana Wu, Marios Giannakis, Shuji Ogino, Andrew D. Cherniack, Jonathan A. Nowak, Brendan Reardon, Rong Zhong, Charles S. Fuchs, Henry Lee-Six, Carino Gurjao, Liam F. Spurr, Xuehong Zhang, Yvonne Y. Li, Tomotaka Ugai
Publikováno v:
Cancer Discov
Several risk factors have been established for colorectal cancer, yet their direct mutagenic effects in patients' tumors remain to be elucidated. Here, we leveraged whole-exome sequencing data from 900 colorectal cancer cases that had occurred in thr
Autor:
Shengbao Suo, Adrienne M. Luoma, Nathanael S. Gray, Julia McCreary, Sara M. Tolaney, Kelly Boelaars, Max Heckler, Eleanor Clancy-Thompson, Kai W. Wucherpfennig, Guo-Cheng Yuan, Tamara Boschert, Thorsten R. Mempel, Michael Dougan, Stephanie K. Dougan, Kevin Roehle, Lestat R. Ali, Henry W. Long, Patrick J Lenehan, Shom Goel, Vera Peters, Li Qiang, Francesco Marangoni, Katherine S. Ventre, Eric S. Wang
Publikováno v:
Cancer discovery, vol 11, iss 10
Cancer Discov
Cancer Discov
CDK4/6 inhibitors are approved to treat breast cancer and are in trials for other malignancies. We examined CDK4/6 inhibition in mouse and human CD8+ T cells during early stages of activation. Mice receiving tumor-specific CD8+ T cells treated with C
Autor:
Nadine Hein, Ella R. Thompson, Richard B. Pearson, Natalie Brajanovski, Ross D. Hannan, Amit Khot, Simon J. Harrison, Grant A. McArthur, Piers Blombery, Elaine Sanij, Donald P. Cameron, Gretchen Poortinga, Karen E. Sheppard, John K.C. Lim, John Soong, Andrew Fellowes, Kylee H Maclachlan, Emma Link
Publikováno v:
Cancer Discovery. 9:1036-1049
RNA polymerase I (Pol I) transcription of ribosomal RNA genes (rDNA) is tightly regulated downstream of oncogenic pathways, and its dysregulation is a common feature in cancer. We evaluated CX-5461, the first-in-class selective rDNA transcription inh
Autor:
Emily E. Van Seventer, Ana Babic, Jeffrey W. Miller, Deborah Knoerzer, Marvin Ryou, Heather A. Shahzade, Nadine Jackson McCleary, Jaegil Kim, Douglas A. Rubinson, Mehlika Hazar-Rethinam, Rebecca J. Nagy, Kristin Anderka, David A. Tuveson, Robert J. Mayer, Scott L. Carter, Leona A. Doyle, Nelly Oliver, Nicholas D. Camarda, Kimmie Ng, Matthew B. Yurgelun, Lauren K. Brais, Levi A. Garraway, Jeffrey A. Meyerhardt, Arezou A. Ghazani, Richard A. Moffitt, Stuart G. Silverman, Thomas E. Clancy, Srivatsan Raghavan, Annacarolina da Silva, Brandon Nadres, James M. Cleary, Andrew J. Aguirre, Kunal Jajoo, Kelly P. Burke, Michael H. Rosenthal, Emma Reilly, Kimberly Perez, Jonathan A. Nowak, Charles S. Fuchs, Dean Welsch, Jen Jen Yeh, Matthew H. Kulke, Marisa W. Welch, William C. Hahn, Anuj K. Patel, Ryan B. Corcoran, Karla Helvie, Paul B. Shyn, Gad Getz, Nikhil Wagle, Dorisanne Y. Ragon, Lori Marini, Geoffrey I. Shapiro, Janet E. Murphy, Brian M. Wolpin, Richard B. Lanman, Devin McCabe, Jason L. Hornick, Bruce E. Johnson, Ewa Sicinska, Joseph P. St. Pierre
Publikováno v:
Cancer Discovery. 8:1096-1111
Clinically relevant subtypes exist for pancreatic ductal adenocarcinoma (PDAC), but molecular characterization is not yet standard in clinical care. We implemented a biopsy protocol to perform time-sensitive whole-exome sequencing and RNA sequencing
Autor:
Elina Tsyvkin, Minhee Won, Nicolaos Palaskas, Katherine S. Panageas, Paolo Codega, Scott Peak, Nikolaus Schultz, I. T. Gavrilovic, Thomas G. Graeber, Ahmet Dogan, Jason T. Huse, Daniel Rohle, Craig S. Sauter, Jon Glass, Viviane Tabar, Carl Campos, Agnes Viale, Craig Nolan, Alissa A. Thomas, Ariela Noy, Derrek Schartz, Vaios Hatzoglou, Julia Wolfe, M. Lia Palomba, Anne S. Reiner, Paul A. Hamlin, Craig H. Moskowitz, Christian Grommes, Thomas Kaley, Cameron Brennan, Enrico C. Lallana, Sarah S. Tang, Lisa M. DeAngelis, Alessandro Pastore, Owen Clark, Philip H. Gutin, Elena Pentsova, Antonio M. P. Omuro, Wan-Ying Hsieh, Marc K. Rosenblum, Donna Nichol, Ingo K. Mellinghoff
Publikováno v:
Cancer Discovery. 7:1018-1029
Bruton tyrosine kinase (BTK) links the B-cell antigen receptor (BCR) and Toll-like receptors with NF-κB. The role of BTK in primary central nervous system (CNS) lymphoma (PCNSL) is unknown. We performed a phase I clinical trial with ibrutinib, the f
Autor:
Aaron M. Newman, Li Zhou, Susan M. Hiniker, Andrew J. Gentles, Philip A. Beachy, Alexander F. Lovejoy, Henning Stehr, William Kong, Justin N. Carter, Maximilian Diehn, Ngoc T. Hoang, Carmen Say, Billy W. Loo, Diana Truong, Robert B. West, Ash A. Alizadeh, Shanique Martin, Aadel A. Chaudhuri, Youngtae Jeong, Diane Heiser
Publikováno v:
Cancer Discovery. 7:86-101
Lung squamous cell carcinoma (LSCC) pathogenesis remains incompletely understood, and biomarkers predicting treatment response remain lacking. Here, we describe novel murine LSCC models driven by loss of Trp53 and Keap1, both of which are frequently
Autor:
Filippo de Braud, Christopher A. French, Emanuele Zucca, Giuseppe Pelosi, Mohamed Bekradda, Anastasios Stathis, Jean Pierre Delord, Carlos Gomez-Roca, Thibault De La Motte Rouge, Emmanuelle Uro-Coste
Publikováno v:
Cancer Discovery. 6:492-500
The antineoplastic, prodifferentiative effects of bromodomain and extra-terminal (BET) bromodomain (BRD) inhibitors were initially discovered in NUT midline carcinoma (NMC), an aggressive subtype of squamous cancer driven by the BRD4–NUT fusion onc
Autor:
Helen Won, Venkatraman E. Seshan, Mark G. Kris, Paul K. Paik, Natasha Rekhtman, Michael F. Berger, Marc Ladanyi, Lu Wang, Camelia S. Sima, Arshi Arora, Ronglai Shen
Publikováno v:
Cancer Discovery. 5:610-621
Large-scale genomic characterization of squamous cell lung cancers (SQCLC) has revealed several putative oncogenic drivers. There are, however, little data to suggest that these alterations have clinical relevance. We performed comprehensive genomic
Autor:
William Pao, Charles Ng, Viviana Bozon, Peilin Jia, Suzanne Branch, Mohammad Atefi, Kimberly B. Dahlman, Antoni Ribas, Katherine E. Hutchinson, Cindy L. Vnencak-Jones, Donald Hucks, James L. Netterville, John A. Glaspy, Zhongming Zhao, Neal Rosen, Jeffrey A. Sosman, Donna J. Hicks, Zengliu Su, Junfeng Xia, David B. Solit, Pamela L. Lyle
Publikováno v:
Cancer Discovery. 2:791-797
Kinase inhibitors are accepted treatment for metastatic melanomas that harbor specific driver mutations in BRAF or KIT, but only 40% to 50% of cases are positive. To uncover other potential targetable mutations, we conducted whole-genome sequencing o